TÜBINGEN, Germany/BOSTON, USA – December 19, 2023 – CureVac N. V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company introducing a new generation of messenger ribonucleic acid (“mRNA”) transformative medicines, announced that BioNTech’s invalidity action against the German part of the patent CureVac EP 1,857,122 B1 has been granted through the German Federal Patent Court. CureVac will appeal to the German Federal Court of Justice.
“We consider the patent court’s decision unfortunate also in view of the positive preliminary opinion on EP 1 857 122 B1 the court provided earlier this year. The decision is only one of many that will be made regarding the use of CureVac’s intellectual property in the development of Comirnaty®. We remain highly confident that our pioneering role in mRNA technology and continuing innovation in the field made essential contributions to safe and efficacious COVID-19 vaccines,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. “While we do not seek to diminish the value of mRNA vaccines in changing the course of the COVID-19 pandemic, we strongly believe that CureVac’s role in laying the scientific groundwork for those vaccines needs to be recognized. We will continue to defend our claim for recognition and fair compensation and will take appropriate action by appealing this decision.”
CureVac is represented in Germany by Oliver Jan Jüngst from Bird & Bird LLP and Andreas Graf von Stosch from Graf von Stosch Patentanwaltsgesellschaft and represented in the U.S. by Mark H. Izraelewicz from Marshall, Gerstein & Borun LLP.
CureVac (Nasdaq: CVAC) is a global biopharmaceutical corporation in the field of messenger RNA (mRNA) generation, with over 20 years of experience in the progression, optimization and production of this flexible biological molecule. medical purposes. The principle of CureVac’s patented generation is the use of optimized mRNA as a knowledge carrier to instruct the human body to produce its own proteins capable of combating a wide diversity of diseases. In July 2020, CureVac entered into a collaboration with GSK to jointly expand new infectious disease prophylactic vaccine products based on CureVac’s second-generation mRNA generation. This collaboration subsequently extended to the progression of second-generation COVID-19 vaccine applicants and changed mRNA vaccine technologies. Building on its proprietary generation, CureVac has built a broad clinical portfolio in the spaces of prophylactic vaccines, anti-cancer treatments, anti-marginal treatments, and rare disease treatments. CureVac N. V. is headquartered in Tübingen, Germany, and has more than 1,100 employees at locations in Germany, the Netherlands, Belgium, Switzerland and the United States. More information can be obtained at www. curevac. com.
CureVac Media & Investor Relations
Dr. Sarah Fakih, Vice President of Corporate Communications and Investor Relations
Similar. : 49 7071 9883-1298
M: +49 160 90 496949
sarah. fakih@curevac. com
CureVac’s Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” as that term is explained in the Private Securities Litigation Reform Act of 1995, including statements that express opinions, expectations, ideals, plans, objectives, assumptions or projections. by CureVac N. V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc. , CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Nederland B. V. (the “Company”) in respect of long-term occasions or performance occasions. effects, contrary to statements that reflect old facts. The examples come with a discussion of the potential effectiveness of the company’s vaccine and remedy applicants, as well as the company’s strategies, financing plans, expansion opportunities, and expanding market position. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “specify. ” expect”, “possibly”, “will”, “would”, “may also simply”, “prospective”, “intends” or “deserves”, the negative form of those terms or explicit similar ones. Forward-looking statements are based on management’s existing ideals and assumptions and the current configuration of the Company. However, such forward-looking statements are not guarantees of the Company’s performance and you should not place undue reliance on them. Forward-looking statements are subject to a variety of risks, uncertainties and other varying circumstances, including negative global economic situations and continued instability and volatility in global money market positions, the ability to discharge financing, the ability to conduct preclinical studies and the current and long-term. execute clinical trials, timing, expense and uncertainty of regulatory approval, dependence on third parties and collaboration partners, ability to commercialize products, ability to manufacture products. Arrange conceivable adjustments to existing and proposed legislation, regulations and government policies, pressures similar to festival expansion and consolidation within the business. industry, effects of the COVID-19 pandemic on the Company’s business and operational effects, ability to manage expansion, dependence on key personnel, dependence on intellectual property coverage, ability to ensure patient safety, fluctuations in operational effects due to the effect of exchange rates, delays in legal proceedings, different legal results or other points. Such dangers and uncertainties could cause the statements to be misleading and readers are cautioned not to place undue reliance on such statements. Many of these hazards are beyond the Company’s control and may also cause their actual effects to differ materially from those expected to occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not assume, and in particular disclaims, any legal responsibility to update such statements or to publicly announce the effects of any revisions to such statements to reflect long-term events or developments, unless required by law.
For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.